Invited Commentary 

Potential Transformative Impact of Autonomous Oxygen Delivery in Hospitalized Patients

Melanie F. Weingart, Michael A. Matthay

JAMA Intern Med Published Online: August 3, 2026

doi: 10.1001/jamainternmed.2026.4038

Oxygen is one of the most commonly administered therapies used in patients with acute illness and hypoxemic respiratory failure, owing to major advances in its delivery and monitoring over the past century. Despite its ubiquity, oxygen therapy in the inpatient setting remains resource intensive, requiring accurate monitoring, repeated adjustments in flow rates by clinical staff, and reliable access to oxygen supplies and delivery devices. As a result, despite designation as an essential medicine by the World Health Organization, access to this life-saving therapy remains constrained in many resource-limited settings.¹ Mortality seems to be higher when oxygen therapy has not been available or not administered optimally.² Technologies that reduce clinical workload and limit excessive oxygen use are therefore a major unmet need.

In this issue of JAMA Internal Medicine, Douin et al³ report the results of a multicenter randomized clinical trial evaluating autonomous oxygen titration in 300 hospitalized patients with acute hypoxemic respiratory failure across 4 US hospitals. Use of the PRO100 device (O2matic) showed statistically significant increased proportion of time spent in normoxemia compared with usual care (85% vs 63%) and considerably reduced the time spent in hypoxemia (2.0% vs 3.6%) over the first 72 hours. These results were consistent across prespecified subgroups, including skin pigmentation, pulmonary comorbidities, and oxygen flow rate at randomization. Notably, 78% of the study population had medium or dark skin pigmentation, enhancing the generalizability of the findings. Although the intervention reduced the total volume of oxygen administered per participant per day, it did not increase supplemental oxygen–free days or reduce progression to more severe respiratory failure. This trial expands on a growing body of evidence supporting autonomous oxygen titration to optimize oxygen delivery in hospitalized patients with hypoxemic respiratory failure.

Autonomous oxygen titration devices have previously been shown to optimize oxygen delivery in patients with COVID-19, with chronic obstructive pulmonary disease, and in those receiving mechanical ventilation.⁴ However, uncertainty remains regarding performance in patient populations with more diverse skin tones because pulse oximeters systematically overestimate oxygen saturation in persons with darker complexions. The results of this trial indicate that autonomous oxygen titration remained effective in a cohort in which the majority had medium or dark skin pigmentation is an encouraging step toward broader implementation.³ The inclusion of participants with darker skin tones is essential given past evidence that patients of racial and ethnic minority groups have been more prone to both occult hypoxemia and missed opportunities for therapies contingent on the identification of hypoxemia compared to their White counterparts.⁵ Additionally, in low- and middle-income countries, 70% of patients do not receive adequate oxygen therapy when faced with acute medical or surgical conditions typically requiring oxygen supplementation.⁶ Therefore, efficient oxygen supplementation is particularly relevant for low- and middle-income countries, where oxygen shortages and limited staffing frequently constrain delivery of this essential therapy.

The mechanisms underlying these findings also merit consideration. In routine care, oxygen delivery is adjusted intermittently. Staff are frequently occupied with other tasks, and changes in oxygen saturation, particularly improvements, may go unnoticed, or clinicians may intentionally leave oxygen higher than necessary as a perceived safety buffer. As a consequence, manual titration is prone to both undercorrection and overcorrection. Autonomous oxygen titration functions as a closed-loop feedback system that continuously monitors oxygen saturation and makes smaller, more precise adjustments in oxygen delivery. Consistent with this mechanism, patients in the intervention arm required fewer flow adjustments greater than 1 L/min.³

Although autonomous titration improved both hypoxemia and hyperoxemia, the reduction in hyperoxemia was substantially larger. Hyperoxemia has long been implicated in the pathophysiology of acute lung injury through the production of reactive oxygen species. However, whether these biological effects translate into worse clinical outcomes and for which patients remains uncertain.⁷ In critically ill patients receiving mechanical ventilation, a conservative oxygen strategy titrated to avoid hyperoxemia did not reduce ventilator-free days, and trials comparing lower and higher oxygenation targets have yielded similar outcomes.^8,9 This brings into question whether hyperoxia in hospitalized patients receiving low-flow oxygen is clinically deleterious. Although autonomous oxygen titration clearly reduces hyperoxemia and excessive resource use, the clinical significance of reducing transient hyperoxemia in patients receiving low-flow supplemental oxygen remains uncertain.

While the findings from the current trial are encouraging, interpretation requires consideration of potential limitations of the study.³ The control group spent considerably less time in hypoxemia than in prior studies. While this likely represents enhanced usual care, as the authors suggest, an alternative explanation could be a selection bias if clinicians preferentially excluded patients at greatest risk of rapid fluctuation in oxygen or deterioration. Additionally, the absolute reduction in proportion of time spent in hypoxemia was modest, and whether these improvements in oxygenation metrics translate into meaningful patient outcomes, including reduced respiratory decompensation, shorter hospital stays or improved survival, remains uncertain. However, the absence of demonstrated patient-centered benefits in this trial should not diminish the potential health system value of technologies that improve oxygen stewardship and reduce resource utilization.

What should be the next priorities for testing the potential clinical value of autonomous oxygen titration devices? In high-resource settings, implementation studies should determine how these systems perform in areas where oxygen requirements fluctuate rapidly and staffing demands are greatest, including emergency departments with prolonged boarding and intermediate care units. Successful integration will require incorporation into existing monitoring and alarm systems, as well as clear safety protocols for sensor disconnection, device failure, and clinician override. In low- and middle-income countries, effectiveness trials should evaluate performance under constrained infrastructure, including environments in which oxygen is delivered solely by concentrators, supply pressures vary, and power interruptions are common.¹⁰ In these settings, conserving oxygen may be as important as optimizing metrics of delivery. Ultimately, the relevant question is not simply whether these devices improve time spent in normoxemia, but whether they enable more patients to be treated safely with finite oxygen resources.

In summary, this well-designed, randomized clinical trial by Douin and colleagues³ demonstrates that autonomous oxygen titration can safely optimize oxygen delivery while reducing oxygen utilization in hospitalized patients requiring low-flow oxygen, with a modest but statistically significant reduction in patients experiencing hypoxemia. Whether these physiological gains translate to improved clinical outcomes and also extend scarce oxygen resources to more patients in low-resource settings are the next critical questions.